Skip to content

Efficacy and safety of ReDuNing Injection in hospitalized uncomplicated Dengue fever patients: a pilot randomized open study.

Efficacy and safety of ReDuNing Injection in hospitalized uncomplicated Dengue fever patients: a pil

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-14005244
Enrollment
Unknown
Registered
2014-09-18
Start date
2014-09-18
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dengue fever

Interventions

control group:Westen medical treatments
test group:Westen medical treatments

Sponsors

1st accessary hospital of Guangzhou University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Age
16 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Consistent with dengue clinical manifestations, with epidemiological history (have been to dengue endemic areas 15 days prior to the onset, dengue cases have occurred in residence), or leukopenia and thrombocytopenia; (2) According to the Guidelines for the diagnosis and treatment of dengue fever(china, 2014), hospitalized patients with highly suspicious of dengue fever mild acute period; (3) To be aged between 16 to 70 years; (4) patients whose under armpit temperatures to be higher than 38.5?; (5) patients who must be voluntary to the trail and sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Severe Dengue fever patients; (2) Patients with secondary infection; (3) With diabetes, coronary heart disease, liver cirrhosis, peptic ulcer, asthma, COPD, Mediterranean anemia, chronic renal dysfunction and other underlying diseases, and glucose 6-phosphate dehydrogenase (G-6-PD) deficiency disease; (4) Obesity or severe malnutrition patients; (5) Allergic constitution (allergic to more than 2 types of material allergy), or allgeric to the composition of the drugs in this study; (6) Inclined to hemolysis patients; (7) Have participated in clinical trials of other drugs within the past 3 months; (8) Other conditions that investigators believe are not suitable for the patients to be enrolled; (9) patients are unsuitble for the experiment considered by the doctors.

Design outcomes

Primary

MeasureTime frame
Time of temperature to nomal;nucleic acid detection of serum pathogeni;

Secondary

MeasureTime frame
Time of clinical symptoms disappeared;Blood analysis;Serum inflammatory factors;Hospitalization tim;

Countries

Guangdong

Contacts

Public ContactYang Zhongqi
yang_zhongqi@163.com+86 13688867618

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026